Liver Diseases Clinical Trial
Official title:
Efficacy Study of Liquid Acupuncture(Herb Acupoint Injection) Therapeutics in Chronic Hepatitis B(CHB) Based on Patients' Individual Condition
Study Purpose:
The purpose of this study is to assess that Liquid Acupuncture(Herb Acupoints Injection)
Therapeutics could achieve permanent efficacy response in Chronic Hepatitis B.
Efficacy Assessment:
At cessation of the Treatment(about at 24 weeks)comparing Testing Data with the Normal
Criteria and their individual baseline.Continue for monitoring the Status 1-5 years.
Data Analysis:
Each 4 weeks collecting Patients' testing data and fill a table.A summary table will be
presented as frequency tables for categorical variables as number or percentage.
Inclusion Criteria & Outcome:
Documented chronic hepatitis B infection positive serum HBV-DNA 10^5 copies/mL & above.
Permanent efficacy response after whole treatment circle close(about 24 weeks,someone may be
later than 24 weeks but within 48 weeks)
- HBeAg loss(if HBeAg positive)
- Liver Function normal(if Liver Function off normal)
- HBV DNA non-detectability (PCR <500 copies/ml)
- Image of chronic diffuse hepatic disease will recover up to normal if have.
- HBsAg titer will decrease continually up to loss after cessation of the treatment.
Treatment Procedure:
Patients will be involved in the study for up to 24-48 weeks from enrollment. There is no
external sponsor, commercial sponsor nor governmental agency on this study. The study will
be conducted only by Dr. Yu, Ke Heng,who is master of the Liquid Acupuncture(Herb Acupoint
Injection)practice more than 30 years.About 30 subjects will be involved in the study
overall. All the subjects can be filled up worldwide.
Patients will be required to rent apartment or house for staying at the city(Xiamen
city,China preferred).Dr. Yu will go to the Patients' site for treatment practice
weekly,each 4 weeks is one circle(the first 3 weeks for treatment practice and last week for
Test collection).Appointed Hospitals for test must be certificated and qualified(Chang Gang
Hospital preferred).Dr. Yu will explain the test results individually.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05255042 -
Tissue Models for Liver Disease
|
||
Completed |
NCT04473482 -
Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Recruiting |
NCT03773887 -
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT00345930 -
DILIN - Prospective Study
|
||
Completed |
NCT00148031 -
Improving Hepatitis C Treatment in Injection Drug Users
|
Phase 4 | |
Terminated |
NCT00031135 -
Total Parenteral Nutrition-Associated Liver Disease
|
Phase 2 | |
Completed |
NCT00005305 -
Hepatitis Delta Infections in Hemophiliacs
|
N/A | |
Completed |
NCT00005304 -
Delta Hepatitis and Liver Disease in Hemophiliacs
|
||
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT06195917 -
Robotic-assisted Percutaneous Transhepatic Puncture
|
N/A | |
Recruiting |
NCT04551742 -
Social & Contextual Impact on Children Undergoing Liver Transplantation
|
||
Completed |
NCT04782050 -
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Recruiting |
NCT05499585 -
Treating Pediatric NAFLD With Nutrition
|
N/A | |
Terminated |
NCT03396705 -
Liver Regeneration
|
||
Completed |
NCT04341012 -
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
|
||
Recruiting |
NCT05733832 -
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
|
N/A |